PT  - JOURNAL ARTICLE
AU  - Parry, Nicola
ED  - Steger, Günther
TI  - Neoadjuvant B and N Safe and Effective with D and H in HER2-Positive Breast Cancer
DP  - 2014 Dec 01
TA  - MD Conference Express
PG  - 11--12
VI  - 14
IP  - 36
4099  - http://mdc.sagepub.com/content/14/36/11.2.short
4100  - http://mdc.sagepub.com/content/14/36/11.2.full
AB  - Neoadjuvant treatment regimens resulting in high pathologic complete response (pCR) rates are needed for patients with HER2-positive breast cancer because they are correlated with favorable prognoses. Although N in combination with H is highly effective in HER2-positive breast cancer, this regimen is unsuitable because of high cardiotoxicity. The Phase 2 Study of Neoadjuvant Trastuzumab+Docetaxel+Non-pegylated Liposome-Encapsulated Doxorubicin (NPLD)±Bevacizumab in HER2-Positive Early Breast Cancer [ABCSG-32; NCT01367028] was conducted to evaluate the cardiotoxicity and efficacy of N and B in combination with DH in the neoadjuvant treatment of early HER2-positive breast cancer.